HC Wainwright Has Pessimistic Outlook of CNTX Q1 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Equities research analysts at HC Wainwright dropped their Q1 2026 EPS estimates for Context Therapeutics in a report issued on Tuesday, March 24th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.14) per share for the quarter, down from their prior forecast of ($0.11). The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.44) EPS and FY2030 earnings at $0.08 EPS.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04).

Other research analysts also recently issued reports about the company. Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. JonesTrading assumed coverage on Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. Piper Sandler increased their price target on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Tuesday. Finally, Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.60.

Context Therapeutics Trading Down 16.0%

Shares of CNTX stock opened at $2.67 on Thursday. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.62. The business’s fifty day simple moving average is $2.44 and its 200-day simple moving average is $1.61. The company has a market cap of $245.32 million, a PE ratio of -7.03 and a beta of 1.96.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CNTX. Clear Harbor Asset Management LLC increased its holdings in Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after buying an additional 35,000 shares during the period. Vanguard Group Inc. raised its position in Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after buying an additional 134,449 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Context Therapeutics during the 3rd quarter valued at approximately $100,000. Blue Owl Capital Holdings LP boosted its holdings in shares of Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Context Therapeutics by 58.8% in the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Key Headlines Impacting Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target from $4.00 to $7.00 and assigned an “overweight” rating, signaling stronger upside expectations. Article Title
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and maintains a $5.00 price target, supporting additional analyst-driven buying interest. Article Title
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” and set a $9.00 target — the most aggressive upside among recent analysts — which can attract momentum investors. Article Title
• Neutral Sentiment: Context released its full-year 2025 operating and financial results; investors will need to parse the report for cash runway, R&D spending, and guidance to judge longer-term impact. Full-Year 2025 Results
• Neutral Sentiment: Multiple short-interest notices cite a “large increase” but report zero shares and NaN changes — this appears to be a data/reporting glitch rather than confirmed new short positions; treat short-interest signals as unreliable until corrected.
• Negative Sentiment: The company reported a quarterly EPS miss on March 23 (reported -$0.14 vs. consensus -$0.10), which is a headwind for sentiment and may be weighing on the stock despite analyst optimism.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.